アトピー性皮膚炎(アトピー性湿疹)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0804
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:639
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Atopic Dermatitis (Atopic Eczema) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis – Pipeline Review, H1 2020, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 50, 24, 4, 54, 23 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 8 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Atopic Dermatitis (Atopic Eczema) – Overview
Atopic Dermatitis (Atopic Eczema) – Therapeutics Development
Atopic Dermatitis (Atopic Eczema) – Therapeutics Assessment
Atopic Dermatitis (Atopic Eczema) – Companies Involved in Therapeutics Development
Atopic Dermatitis (Atopic Eczema) – Drug Profiles
Atopic Dermatitis (Atopic Eczema) – Dormant Projects
Atopic Dermatitis (Atopic Eczema) – Discontinued Products
Atopic Dermatitis (Atopic Eczema) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Companies, H1 2020 (Contd..10), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Atopic Dermatitis (Atopic Eczema) - Pipeline by 3SBio Inc, H1 2020
Atopic Dermatitis (Atopic Eczema) - Pipeline by Abate Med Inc, H1 2020
Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, H1 2020
Atopic Dermatitis (Atopic Eczema) - Pipeline by Abeome Corp, H1 2020
Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020
Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..2), H1 2020
Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..3), H1 2020
Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..4), H1 2020
Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..5), H1 2020
Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..6), H1 2020
Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..7), H1 2020
Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..8), H1 2020
Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..9), H1 2020
Atopic Dermatitis (Atopic Eczema) - Discontinued Products, H1 2020
Atopic Dermatitis (Atopic Eczema) - Discontinued Products, H1 2020 (Contd..1), H1 2020

【掲載企業】

3SBio Inc
Abate Med Inc
AbbVie Inc
Abeome Corp
Aclaris Therapeutics Inc
Afecta Pharmaceuticals Inc
Akaal Pharma Pty Ltd
Akeso Biopharma Inc
Allergan Plc
Amgen Inc
Amorepacific Corp
AOBiome LLC
Apimeds Inc
Arcutis Biotherapeutics Inc
Arena Pharmaceuticals Inc
Arrien Pharmaceuticals LLC
Asana BioSciences LLC
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
AstraZeneca Plc
Atrapos Therapeutics LLC
Azitra Inc
Bausch Health Companies Inc
Biomimetix JV LLC
Blueberry Therapeutics Ltd
Boehringer Ingelheim International GmbH
Botanix Pharmaceuticals Ltd
Calcico Therapeutics Ltd
Chugai Pharmaceutical Co Ltd
Clayton Biotechnologies Inc
Clevexel Pharma SAS
CSA Biotechnologies LLC
Cutanea Life Sciences Inc
Daiichi Sankyo Co Ltd
Dermata Therapeutics LLC
Dermavant Sciences Inc
DermBiont Inc
Devonian Health Group Inc
DongKoo Bio & Pharma Co Ltd
DURECT Corp
EHL Bio Co Ltd
Eli Lilly and Co
Enzychem Lifesciences Corp
Evelo Biosciences Inc
Evotec SE
F. Hoffmann-La Roche Ltd
Galapagos NV
Galderma SA
General Regeneratives Shanghai Ltd
GI Innovation Co Ltd
Helix BioMedix Inc
Hill Dermaceuticals Inc
Hoth Therapeutics Inc
Huons Co Ltd
Ichnos Sciences Inc
Immune Pharmaceuticals Inc
Incyte Corp
Inflamalps SA
Innovation Pharmaceuticals Inc
Innovimmune Biotherapeutics Inc
Integral Molecular Inc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
Jubilant Biosys Ltd
JW Pharmaceutical Corp
Kang Stem Biotech Co Ltd
Kine Sciences
Kiniksa Pharmaceuticals Ltd
KoBioLabs Inc
Krystal Biotech Inc
Kv1.3 Therapeutics
Kymab Ltd
Kyowa Kirin Co Ltd
Larix Bioscience LLC
Lead Pharma Holding BV
Lemonex Inc
Leo Pharma AS
Lipid Biologics LLC
Matrisys Bioscience Inc
MC2 Therapeutics AS
Medicenna Therapeutics Corp
Micreos BV
Nektar Therapeutics
Nepsone ehf
Neuracle Science Co Ltd
Next Science Ltd
NovaCell Technology Inc
Novan Inc
Novartis AG
Oasis Pharmaceuticals LLC
OliX Pharmaceuticals Inc
Ondek Pty Ltd
Oneness Biotech Co Ltd
Orbis Biosciences Inc
Otsuka Holdings Co Ltd
Pantherics Inc
Pfizer Inc
Polyrizon Ltd
Portola Pharmaceuticals Inc
Provectus Biopharmaceuticals Inc
Pyramid Biosciences Inc
Qurient Co Ltd
Ralexar Therapeutics Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Ribomic Inc
SCM lifescience Co Ltd
Seelos Therapeutics, Inc.
Servatus Ltd
Shaperon Inc
Shulov Innovative Science Ltd
Sienna Biopharmaceuticals Inc
Signum Biosciences Inc
Signum Dermalogix Inc
siRNAgen Therapeutics Corp
Sosei Heptares
Spherium Biomed SL
StemRIM Inc
sterna biologicals Gmbh & Co KG
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Temisis Therapeutics
The Geneva Biotech Center SA
Therabest Co Ltd
Tianjin Hemay Pharmaceutical Co Ltd
Tolerys SA
Torrent Pharmaceuticals Ltd
Transdermal Therapeutic Technologies LLC
Union Therapeutics AS
United Biomedical Inc
Vasomune Inc
VivaCell Biotechnology Espana SL
Voronoi
vTv Therapeutics Inc
Welichem Biotech Inc
Zhejiang I-Biological Technology Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アトピー性皮膚炎(アトピー性湿疹)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆